AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 18455052
Drug: Raffle ticket
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Raffle ticket activated with influenza vaccine administration for a free Caribbean vacation for 2
Trial: 16821420
Drug: somatotropic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: somatotropic therapy + coaxil (37.5 mg/day for 6 weeks; 25 mg/day for patients over 70 years)
Trial: 16821420
Drug: somatotropic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: somatotropic therapy + coaxil
Trial: 16821420
Drug: somatotropic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: somatotropic therapy alone (control group)
Trial: 15366592
Drug: Integrative Chinese
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Integrative Chinese and Western medicine (ICWM)
Trial: 14571610
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (Western medicine)
Trial: 10737842
Drug: Amoxicillin (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxicillin (50 mg/kg per day for 7 days)
Trial: 3905210
Drug: Bromocriptine (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bromocriptine (2.5 mg/day orally)
Trial: 29248173
Drug: Tube shunt
RxNorm normalized name: Sus scrofa fallopian tube preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tube shunt (350‐mm2 Baerveldt glaucoma implant)
Trial: 24534125
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of automated Internet psycho-educational training program and Internet Support Group (ISG)
Trial: 20548043
Drug: Cognitive-behavioral therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-behavioral therapy (CBT) plus standard medical care (SMC)
Trial: 15961004
Drug: Levalbuterol (LEV)
DrugBank: Levosalbutamol (DB13139)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Levalbuterol (LEV) - <or=6 nebs LEV 1.25 mg
Trial: 15961004
Drug: Racemic albuterol
RxNorm normalized name: Albuterol
DrugBank: Albuterol (DB01001)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Racemic albuterol (RAC) combined with ipratropium bromide (IB) - <or=3 nebs RAC 5.0 mg + IB 0.25 mg followed as needed by <or=3 nebs RAC 5.0 mg
Trial: 10433013
Drug: Anti-carbonic anhydrase
RxNorm normalized name: Anti Bac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-carbonic anhydrase II antibody testing in patients with PBC (n=40)
Trial: 10433013
Drug: Anti-carbonic anhydrase
RxNorm normalized name: Anti Bac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-carbonic anhydrase II antibody testing in patients with AIC (n=23)
Trial: 10433013
Drug: Anti-carbonic anhydrase
RxNorm normalized name: Anti Bac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-carbonic anhydrase II antibody testing in healthy subjects (n=24)
Trial: 10433013
Drug: Anti-carbonic anhydrase
RxNorm normalized name: Anti Bac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-carbonic anhydrase II antibody testing in patients with autoimmune hepatitis (n=10)
Trial: 10433013
Drug: Anti-carbonic anhydrase
RxNorm normalized name: Anti Bac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-carbonic anhydrase II antibody testing in patients with obstructive jaundice (n=10)
Trial: 1387774
Drug: Ondansetron 4
RxNorm normalized name: ondansetron 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ondansetron 4 mg orally once daily for 3-5 consecutive days
Trial: 6660847
Drug: Amoxicillin combined
RxNorm normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amoxicillin combined with clavulanic acid (ACA)
Trial: 29289538
Drug: Omega-3 carboxylic
RxNorm normalized name: omega-3 carboxylic acids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omega-3 carboxylic acids (OM3-CA) 2 g daily
Trial: 29289538
Drug: Olive oil
RxNorm normalized name: Olive Oil
DrugBank: Olive oil (DB09567)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olive oil 2 g daily
Trial: 27091416
Drug: Control (patient's
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (patient's choice with physician's advice of low-dose cytarabine or supportive care)
Trial: 21889769
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy with statins and fenofibric acid (FA)
Trial: 10548322
Drug: High-fruit and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-fruit and -vegetable diet (9 daily servings)
Trial: 2006616
Drug: Nifedipine (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nifedipine (20 mg 3 times daily)
Trial: 7124629
Drug: Verapamil (120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Verapamil (120 mg 3 times daily)
Trial: 28662808
Drug: Metallic drug-eluting
RxNorm normalized name: Fraxinus velutina pollen
DrugBank: Fraxinus velutina pollen (DB10455)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metallic drug-eluting stent (DES)
Trial: 30728074
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose Shilajit (500 mg·d‐1)
Trial: 30728074
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose Shilajit (250 mg·d‐1)
Trial: 28068560
Drug: Sarpogrelate 300
RxNorm normalized name: Sarpogrelate
DrugBank: Sarpogrelate (DB12163)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sarpogrelate 300 mg/day plus aspirin 100 mg/day (SPG + ASA group)
Trial: 28068560
Drug: Aspirin 100
RxNorm normalized name: aspirin 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin 100 mg/day alone (ASA group)
Trial: 26091087
Drug: telephone-delivered cognitive
RxNorm normalized name: DELIVER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: telephone-delivered cognitive behavioural treatment (CBT) for 8 weeks
Trial: 24919799
Drug: Needling device
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Needling device treatment (3 treatments at 2-week intervals)
Trial: 23390653
Drug: Original stimulating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Original stimulating programs for correction of cognitive decline (computer programs, 20-30 minutes daily, 5 times a week for 14 days)
Trial: 23390653
Drug: Traditional methods
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Traditional methods of treatment
Trial: 12205254
Drug: Sucrose (0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sucrose (0.1 mL of 24%) administered orally up to 3 times, 2 minutes apart for every invasive procedure during a 7-day period
Trial: 12205254
Drug: Sterile water
RxNorm normalized name: sterile water
DrugBank: Water (DB09145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sterile water administered orally up to 3 times, 2 minutes apart for every invasive procedure during a 7-day period
Trial: 30909680
Drug: Thiocochlicoside (group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thiocochlicoside (group A) along with paracetamol and lornoxicam I.V.
Trial: 30909680
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (group B) without thiocochlicoside, receiving paracetamol and lornoxicam I.V.
Trial: 25837041
Drug: Endoscopic lung
RxNorm normalized name: beef lung preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endoscopic lung sealant (ELS) plus medical treatment
Trial: 22905666
Drug: Epidural tramadol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural tramadol (3 mg/kg)
Trial: 22905666
Drug: Epidural lignocaine
RxNorm normalized name: lidocaine hydrochloride Injectable Solution [Sure-Amp Lignocaine hydrochloride]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural lignocaine (4 mg/kg)
Trial: 17704869
Drug: Rofecoxib 25
RxNorm normalized name: rofecoxib 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rofecoxib 25 mg PO, Metoclopramide 10 mg, Dexamethasone 4 mg, Ondansetron 4 mg IV
Trial: 11798012
Drug: Panax ginseng
RxNorm normalized name: Panax Ginseng
DrugBank: Ginseng (DB01404)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Panax ginseng (PG) - 2 g/day dried root equivalent
Trial: 11798012
Drug: Eleutherococcus senticosus
RxNorm normalized name: Eleutherococcus Senticosus Root
DrugBank: Eleuthero (DB14303)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eleutherococcus senticosus (ES) - 4 g/day dried root equivalent
Trial: 7849498
Drug: Clonidine (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clonidine (300 micrograms orally, 1 h prior to morphine)
Trial: 3347080
Drug: Alcohol (0.8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alcohol (0.8 ml of absolute alcohol per kg of body weight)
Trial: 29737150
Drug: Pycnogenol® 150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pycnogenol® 150 mg/day
Trial: 20798386
Drug: High-dose isoflavones
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose isoflavones (20 g of soy protein containing 160 mg of total isoflavones)
Trial: 20798386
Drug: Placebo (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (20 g whole milk protein)
Trial: 20798386
Drug: High-dose isoflavones
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose isoflavones
Trial: 18781287
Drug: Topical azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Topical azithromycin ophthalmic solution 1% plus warm compresses
Trial: 16569248
Drug: Early administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early administration of atropine during dobutamine stress echocardiogram (group C at 40 mcg/kg/min of dobutamine)
Trial: 14599854
Drug: Intravenous daclizumab
RxNorm normalized name: Daclizumab
DrugBank: Daclizumab (DB00111)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Intravenous daclizumab infusions (anti-IL-2 receptor alpha)
Trial: 14599854
Drug: Subcutaneous daclizumab
RxNorm normalized name: Daclizumab
DrugBank: Daclizumab (DB00111)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Subcutaneous daclizumab formulation
Trial: 14599854
Drug: Intravenous daclizumab
RxNorm normalized name: Daclizumab
DrugBank: Daclizumab (DB00111)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Intravenous daclizumab infusions (6-week intervals)
Trial: 14599854
Drug: Intravenous daclizumab
RxNorm normalized name: Daclizumab
DrugBank: Daclizumab (DB00111)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Intravenous daclizumab infusions (2- to 4-week intervals)
Trial: 7570621
Drug: Inhalation exposure
RxNorm normalized name: Bacillus anthracis strain V770-NP1-R antigens
DrugBank: Anthrax vaccine (DB11003)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhalation exposure to toluene diisocyanate (TDI) vapors
Trial: 18362100
Drug: Cod liver
RxNorm normalized name: Cod Liver Oil
DrugBank: Cod liver oil (DB11321)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cod liver oil (10 g containing 2.2 g of n-3 EFAs)
Trial: 18362100
Drug: Placebo (air-filled
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (air-filled identical capsules)
Trial: 1358003
Drug: High-dose esmolol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose esmolol (300 micrograms.kg‐1.min‐1)
Trial: 1358003
Drug: Medium-dose esmolol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medium-dose esmolol (200 micrograms.kg‐1.min‐1)
Trial: 1358003
Drug: Low-dose esmolol
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose esmolol (100 micrograms.kg‐1.min‐1)
Trial: 2997306
Drug: Pentopril (CGS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pentopril (CGS 13945) 125 mg capsules administered in the fasting state
Trial: 2997306
Drug: Pentopril (CGS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pentopril (CGS 13945) 125 mg capsules administered after ingestion of a standardized meal
Trial: 30887250
Drug: PF-06650808 at
RxNorm normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PF-06650808 at dose levels ≤2.0 mg/kg
Trial: 30236568
Drug: Warm intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warm intravenous fluids (Ringer's solution at 38°C)
Trial: 30236568
Drug: Room temperature
RxNorm normalized name: ROOM DEODORIZER POWDER MENTOR #3202
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Room temperature intravenous fluids (Ringer's solution)
Trial: 25008546
Drug: Tozadenant 120
RxNorm normalized name: Tozadenant
DrugBank: Tozadenant (DB12203)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tozadenant 120 mg twice daily
Trial: 25008546
Drug: Tozadenant 180
RxNorm normalized name: Tozadenant
DrugBank: Tozadenant (DB12203)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tozadenant 180 mg twice daily
Trial: 21753727
Drug: NGX-4010 (capsaicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NGX-4010 (capsaicin 8% patch)
Trial: 22067661
Drug: Low-dose capsaicin
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose capsaicin (0.04% control patch)
Trial: 22067661
Drug: Low-dose capsaicin
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose capsaicin (30-minute control)
Trial: 22067661
Drug: Low-dose capsaicin
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose capsaicin (60-minute control)
Trial: 19400487
Drug: Hypobaric bupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypobaric bupivacaine 0.15% 4.5 mg (3 ml)
Trial: 19400487
Drug: Hypobaric bupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypobaric bupivacaine 0.15% 6.0 mg (4 ml)
Trial: 19400487
Drug: Hypobaric bupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypobaric bupivacaine 0.15% 7.5 mg (5 ml)
Trial: 14722542
Drug: Hyoscine N-butyl
RxNorm normalized name: n-butyl acrylate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyoscine N-butyl bromide (40 mg)
Trial: 3400079
Drug: Acitretin (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acitretin (100 mg)
Trial: 3400079
Drug: Etretinate (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etretinate (100 mg)
Trial: 30821829
Drug: Statin therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Statin therapy for 5 years (HPS trial)
Trial: 27262301
Drug: FEC-chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FEC-chemotherapy
Trial: 26701648
Drug: Intravenous thrombolysis
RxNorm normalized name: thrombocytin
DrugBank: Serotonin (DB08839)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous thrombolysis (rt-PA)
Trial: 10352369
Drug: Standardized acupuncture
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standardized acupuncture treatment
Trial: 29572107
Drug: Loteprednol etabonate
RxNorm normalized name: Loteprednol Etabonate
DrugBank: Loteprednol etabonate (DB14596)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Loteprednol etabonate 0.5% ophthalmic suspension
Trial: 25966339
Drug: cART initiated
RxNorm normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: cART initiated one week after TB therapy
Trial: 25966339
Drug: cART initiated
RxNorm normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: cART initiated four weeks after TB therapy
Trial: 25966339
Drug: cART initiated
RxNorm normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: cART initiated eight weeks after TB therapy
Trial: 23089653
Drug: Intraoral mucoadhesive
RxNorm normalized name: testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intraoral mucoadhesive tablet of amitriptyline
Trial: 22358273
Drug: BiPAP® group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BiPAP® group (BG) with conventional respiratory therapy and BiPAP® for 30 minutes twice a day
Trial: 22358273
Drug: Control Group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control Group (CG) with conventional respiratory therapy only
Trial: 6655704
Drug: Sex therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sex therapy
Trial: 12708976
Drug: DB PCFC
RxNorm normalized name: miconazole
DrugBank: Miconazole (DB01110)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: DB PCFC with metabisulfite‐free seasoning (up to 1340 mg)
Trial: 8811328
Drug: High lipid
RxNorm normalized name: guggul lipids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High lipid meal (whipped cream)
Trial: 1547673
Drug: Long-acting zinc
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Long-acting zinc insulin (Ultratard HM) before the evening meal
Trial: 1547673
Drug: Intermediate isophane
RxNorm normalized name: insulin isophane
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermediate isophane insulin (Protaphane HM) before the evening meal
Trial: 21638048
Drug: Toremifene (TOR)
DrugBank: Toremifene (DB00539)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Toremifene (TOR) 40 mg daily
Trial: 21638048
Drug: Anastrozole (ANA)
RxNorm normalized name: Anastrozole
DrugBank: Anastrozole (DB01217)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Anastrozole (ANA) 1 mg daily
Trial: 11886769
Drug: 7-day transdermal
RxNorm normalized name: buprenorphine
DrugBank: Buprenorphine (DB00921)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 7-day transdermal sequential estradiol/levonorgestrel patch (Fem7 Combi; 50 microg estradiol/10 microg levonorgestrel per 24 h)
Trial: 7999858
Drug: Recombinant human
RxNorm normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Recombinant human growth hormone (rhGH) at a dosage of 28-30 IU/m2/week for at least 12 months
Trial: 3045717
Drug: Norfloxacin 400
RxNorm normalized name: norfloxacin 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Norfloxacin 400 mg twice daily for three days
Trial: 3045717
Drug: Trimethoprim 300
RxNorm normalized name: trimethoprim 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trimethoprim 300 mg once daily for three days
Trial: 27843040
Drug: Rivaroxaban 10
RxNorm normalized name: rivaroxaban 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rivaroxaban 10 mg by mouth daily starting postoperative day 1 for 15 days
Trial: 8826488
Drug: 5% lidocaine
RxNorm normalized name: LIDOCAINE 5 g in 100 g TOPICAL CREAM [Healcome Tattoo Numbing Cream 5% Lidocaine]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5% lidocaine patches applied for 12 hours in two of four sessions
Trial: 8826488
Drug: Vehicle patches
RxNorm normalized name: meningococcal group B vaccine / Neisseria meningitidis serogroup B recombinant FHBP fusion protein antigen / Neisseria meningitidis serogroup B recombinant NHBA fusion protein antigen / Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle Prefilled Syringe [Bexsero]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vehicle patches applied for 12 hours in one session
Trial: 8826488
Drug: No-treatment observation
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No-treatment observation session
Trial: 30382274
Drug: Daily dose
RxNorm normalized name: LENVIMA 8mg Daily Dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily dose of 8 g of dried grape pomace
Trial: 22525652
Drug: Creatine ingestion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Creatine ingestion (0.3 g/kg/die for 5 consecutive days)
Trial: 7677387
Drug: Moxonidine 0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moxonidine 0.1 mg
Trial: 2196934
Drug: Doxycycline 200
RxNorm normalized name: doxycycline 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxycycline 200 mg orally at the time of IUCD insertion
Trial: 31632316
Drug: Endotoxin administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Endotoxin administration
Trial: 24915210
Drug: Nasal mupirocin
RxNorm normalized name: mupirocin Nasal Ointment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nasal mupirocin ointment applied twice daily for 5 days before surgery
Trial: 24915210
Drug: Nasal povidone-iodine
RxNorm normalized name: povidone-iodine Nasal Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nasal povidone-iodine solution applied twice into each nostril within 2 hours of surgical incision
Trial: 18378381
Drug: Simvastatin (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simvastatin (10 mg/day)
Trial: 11477342
Drug: Gemfibrozil (dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemfibrozil (dose adjusted for renal function)
Trial: 9667249
Drug: 9-aminocamptothecin (9-AC)
RxNorm normalized name: 9-aminocamptothecin
DrugBank: 9-aminocamptothecin (DB12515)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 9-aminocamptothecin (9-AC) infused over 72 hours at an initial dose rate of 40 microg/m2/h every 3 weeks with dose adjustments based on toxicity.
Trial: 9667249
Drug: Granulocyte-colony stimulating
RxNorm normalized name: Granulocyte colony-stimulating factor pegfilgrastim
DrugBank: Pegfilgrastim (DB00019)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Granulocyte-colony stimulating factor (G-CSF) administered to the subsequent 29 patients on all cycles.
Trial: 8092339
Drug: Naltrexone, 50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naltrexone, 50 mg p.o.